Showing 2201-2210 of 6036 results for "".
- Market Scope: Robotic Vitrectomy Debate Still Rages for Retina Surgeonshttps://modernod.com/news/market-scope-robotic-vitrectomy-debate-still-rages-for-retina-surgeons/2480773/The future of robotic vitrectomy continues to be top of mind for retina surgeons, with panelists at nearly every major retina meeting in 2021 debating the topic—and without reaching co
- Study Lays Foundation for Establishing Base Editing as a One-Time, Durable Treatment for Inherited Retinal Degenerationhttps://modernod.com/news/study-lays-foundation-for-establishing-base-editing-as-a-one-time-durable-treatment-for-inherited-retinal-degeneration/2480766/A new University of California, Irvine-led study indicates base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis (LCA) patients. “Our findings demo
- Harvard Eye Associates Surgeons Implant the First AccuraSee IOPCL to Treat Macular Degenerationhttps://modernod.com/news/harvard-eye-associates-surgeons-implant-the-first-accurasee-iopcl-to-treat-macular-degeneration/2480721/Harvard Eye Associates reported that its surgeons have implanted the first AccuraSee Intraocular Pseudophakic Contact Lens (IOPCL) to improve near vision in patients with macular degeneration. The AccuraSee lens implant is placed to help magnify images and allow patients to use parts of
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer/2480678/EyePoint Pharmaceuticals announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings more than 30 years of global regulatory affairs experience across all phases of drug development, including ophthalmic and ocular conditions. Ms. Lefebvre is su
- Glaukos Announces Executive Leadership Changeshttps://modernod.com/news/glaukos-announces-executive-leadership-changes/2480628/Glaukos announced several executive leadership changes to support the company’s future growth and strategic plans. The following executive changes will become effective on April 1, 2022: Joseph Gilliam will assume the new role of President and Chief Operating Officer.
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/uc-irvine-researchers-reveal-molecular-mechanisms-of-eye-disease-using-cryo-electron-tomography/2480586/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed, at a molecular level, key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrument
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/using-cryo-electron-tomography-uci-researchers-reveal-molecular-mechanisms-underlying-mutations-within-the-eye-that-lead-to-blindness/2480552/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed at a molecular level key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrum
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin